http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2370269-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_601c1203d074153e89f4858f93e5cb66
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61G10-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61H33-14
filingDate 2006-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2009-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b06abd7df4f9cd8967f0d6c22a9316d4
publicationDate 2009-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2370269-C2
titleOfInvention Method of malignant tumor treatment and gas composition (versions) for its realisation
abstract FIELD: medicine. n SUBSTANCE: inventions relate to medicine, namely to oncology, and can be applied in complex treatment of patients with malignant neoplasms. For this purpose introduction of medications possessing antitumor activity is combined with carrying out barotherapy sessions. For each session of barotherapy pressure 0.3-10 kg/cm 2 and atmosphere gas composition are formed in pressure chamber. Gas composition can include air, inert gas or mixture of inert gases, saturated acyclic hydrocarbon or their mixture, as well as ozone and dioxide or protoxide of nitrogen in different combinations and volume ratios. Barotherapy is realised in 1-5 courses. One course includes 10-30 sessions, 1-2 sessions per day with interval between them 0.5-5.0 days. Duration of each session constitutes 0.5-2.0 hours. Between barotherapy courses intervals of 1-2 months are made. Medications of antitumor activity are introduced on days when barotherapy is carried out 0.5-5.0 hours after carrying out corresponding session. n EFFECT: inventions ensure slowing down of tumor growth and its regression, as well as reduction of metastases due to optimal effect of antitumor medications, introduced against the background of weakening of structure interaction and cell metabolism in tumor tissues, arising as a result of inert gases and acyclic hydrocarbons influence on protein polymer chains in tumor. n 15 cl, 13 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2678927-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2695350-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2713455-C2
priorityDate 2006-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449436752
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23991
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419569943
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23935
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID297
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415806325
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415803663
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5453
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419481811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID455728551
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23987
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7843
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419539344
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19427205
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID98818
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559478
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419527425
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6334
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419577374
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53888573
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414021757
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456979502
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556968
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419569950
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419569951
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID948
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID101175
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24823
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5416
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23968
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID43834305
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6360
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458357694
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453266603

Total number of triples: 51.